Testing a TNF-blocking drug to reduce death in HIV and TB meningitis
Treatments studied
Part of Brain & nervous system, Infections clinical trials.
This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have HIV infection
- Have definite or probable TB meningitis
- Start standard TB meningitis treatment no more than 3 days ago (including anti-TB drugs at standard doses and high-dose dexamethasone)
- Be able to give consent (you or a close relative) for study participation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a stronger combination of TB drugs for meningitis can save more lives. It's for patients who have been diagnosed with tuberculosis meningitis and have not yet started more than 5 days of TB treatment.
This study tests a shorter, more intensive treatment for tuberculosis that affects the brain. It may help reduce side effects while still curing the infection.
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
This trial tests if taking N-acetylcysteine (NAC) alongside standard TB treatment can help prevent long-term lung problems after tuberculosis. It is for people with moderate to severe TB who already have some reduced lung function.
This trial studies whether atorvastatin (a cholesterol medicine) can reduce ongoing inflammation after you finish standard tuberculosis (TB) treatment. If it works, it may improve how your body recovers after TB, especially by lowering inflammation-related signals.
This study tests an experimental vaccine (ID93 + GLA-SE) given alongside standard tuberculosis (TB) treatment. It aims to see if the vaccine can improve the body's response to TB treatment and reduce the chance of TB coming back.
Hear when a new Tuberculous Meningitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.